5 Ongoing Clinical Trials in Myeloproliferative Neoplasms

Why It Matters

These late‑stage studies could broaden treatment options for MPNs, addressing unmet needs such as anemia, thrombocytopenia, and resistance to existing drugs, and may reshape the hematology market.

Key Takeaways

• P1101 trial enrolls 111 PV patients to assess hematologic response.
• THRIVE evaluates rusfertide in 46 PV patients to reduce phlebotomies.
• INDEPENDENCE tests luspatercept in 313 MF patients needing transfusions.
• SURPASS-ET compares ropeginterferon to anagrelide in 174 high‑risk ET patients.
• PACIFICA randomizes 407 MF patients to pacritinib versus physician’s choice.

Pulse Analysis

Myeloproliferative neoplasms, though rare, present a significant clinical challenge due to uncontrolled proliferation of blood cells and complications such as anemia, thrombosis, and progression to leukemia. Existing therapies—including JAK inhibitors, hydroxyurea, and interferons—provide symptom control but often fall short for patients who develop resistance or intolerable side effects. Consequently, the pipeline of novel agents is critical for improving survival and quality of life, and the current wave of phase 3 trials reflects a strategic push to fill these therapeutic gaps.

The five highlighted studies each target distinct disease subsets and mechanisms. P1101 and SURPASS‑ET leverage next‑generation pegylated interferon to achieve deeper hematologic remission in polycythemia vera and essential thrombocythemia, respectively. THRIVE’s hepcidin‑mimetic rusfertide aims to curb the need for phlebotomy by modulating iron homeostasis, a novel approach for PV management. INDEPENDENCE evaluates luspatercept, an erythroid‑maturation agent, to reduce transfusion dependence in myelofibrosis patients already on JAK2 inhibitors. PACIFICA tests pacritinib, a kinase inhibitor, specifically in MF patients with severe thrombocytopenia, addressing a high‑risk cohort often excluded from other trials.

If successful, these trials could reshape the MPN therapeutic landscape. Interferon‑based regimens may become first‑line options, while agents like rusfertide and luspatercept could expand the armamentarium for patients with refractory disease or specific cytopenias. For investors and biotech firms, positive outcomes would validate sizable market opportunities, given the estimated 150,000 MPN patients in the United States alone. Moreover, the data may inform combination strategies, accelerating personalized treatment pathways and potentially improving long‑term survival across the MPN spectrum.